Ligand Pharmaceuticals | LGND - 销售和管理费用



金融业
股票价格
USD
资产
USD 1.53B
现金及等价物
USD 115.08M
销售成本
USD 11.37M
流动资产
USD 865.42M
流动负债
USD 40.67M
债务
USD 451.49M
EBIT
USD 60.33M
EBITDA
USD 66.78M
员工
68
EPS每股收益
USD 1.63
股本和储备
USD 997.32M
销售毛利
USD 48.45M
债务利息支出
USD 1.79M
利息收入
USD 6.39M
贷款资金
USD 446.19M
市值
USD 5.66B
净收入
USD -13.35M
营业费用
USD 34.35M
营业利润
USD 60.33M
普通股股本
USD 19.66M
PE价格收益
56.5
税前利润
USD 56.78M
销售收入
USD 51.72M
销售和管理费用
USD 20.84M
股票
USD 13.27M
贸易债权人
USD 37.11M
应收帐款人
USD 54.8M


销售和管理费用 更改 日
Agenus USD 10.56M 13.04M 2025-12
Amgen USD 1.58B 354M 2026-03
Anika Therapeutics USD 10.01M 14K 2025-12
Arrowhead Research USD 41.74M 4.28M 2026-03
Baxter International USD 728M 33M 2026-03
Bristol-Myers Squibb USD 1.62B 564M 2026-03
Eli Lilly USD 2.93B 198M 2026-03
Enanta Pharmaceuticals USD -1.05 0.31 2024-12
Enviri Corporation USD 104.1M 10.81M 2025-12
Gilead Sciences USD 1.45B 326M 2026-03
GlaxoSmithKline GBP 2.12B 558M 2026-03
Glaxosmithkline GBP 2.12B 1.44B 2026-03
Heron Therapeutics USD 23.74M 605K 2025-12
Insmed USD 247.26M 34.78M 2026-03
Intrexon USD 10.31M 41K 2024-06
Ionis Pharmaceuticals USD 151M 21M 2026-03
Karyopharm Therapeutics USD 9.56M 17.63M 2025-12
Ligand Pharmaceuticals USD 20.84M 4.19M 2026-03
MacroGenics USD 9.71M 1.77M 2026-03
Merck USD 2.67B 180M 2026-03
Pacira USD 83.88M 7.99M 2026-03
Pfizer USD 2.92B 1.16B 2026-03
Rigel Pharmaceuticals USD 27.04M 1M 2024-09
Sangamo BioSciences USD 9.64M 1.83M 2024-06
Veracyte USD 50.84M 7.53M 2026-03